NEW YORK — Swiss healthcare firm Roche said Monday that it intends to invest $50 billion over the next five years into expanding its footprint in the US.
According to Roche, the money will be used in part for a new research and development center in Massachusetts that will conduct AI research and act as a hub for the company's cardiovascular, renal, and metabolism programs.
The funds will also go toward a gene therapy manufacturing facility in Pennsylvania, as well as expanded and upgraded manufacturing, distribution, and R&D sites in Kentucky, Indiana, New Jersey, Oregon, Arizona, and California for its medicines and diagnostics portfolio. Also planned are a new manufacturing facility for continuous glucose monitoring technologies in Indiana and manufacturing center for weight-loss medicines in a to-be-announced location.
Roche said that the investment is expected to create more than 12,000 new jobs in the US including 1,000 at the company itself and over 11,000 in fields that will support the planned expansions such as construction.
The company said that once the new and expanded manufacturing capacity is fully operational, it will export more medicines from the US than it imports. Roche noted that its diagnostics division already has an export surplus from the US.
The announced investments "underscore our long-standing commitment to research, development, and manufacturing in the US," Roche Group CEO Thomas Schinecker said in a statement.
Roche's announcement comes on the heels of a series of broad tariffs implemented by the Trump administration with uncertain impacts on the life science industry.